A case of pathological complete response after combination chemotherapy by sorafenib and cisplatin hepatic arterial infusion for an advanced hepatocellular carcinoma

Seiji Oguro, Satoshi Nara, Shunsuke Kondo, Shutaro Hori, Yoji Kishi, Minoru Esaki, Kazuaki Shimada, Tomoo Kosuge, Takuji Okusaka, Hidenori Ojima

Research output: Contribution to journalArticle

Abstract

Sorafenib has emerged as an effective new drug for advanced hepatocellular carcinoma. Until now, however, only a few authors have reported reduction of an advanced hepatocellular carcinoma after treatment including sorafenib, with subsequent resection. We present a case of an advanced hepatocellular carcinoma resected following combination therapy by sorafenib and cisplatin transcatheter arterial infusion. A 56-year-old man with alcoholic liver disease underwent 6 courses of combination chemotherapy by sorafenib (400 mg orally, twice daily) and cisplatin transcatheter arterial infusion (65 mg/m2, every 4-6 weeks) for a hepatocellular carcinoma in the right liver measuring 9 cm in diameter with tumor thrombi in the main portal vein and the inferior vena cava. The tumor showed stable disease according to RECIST criteria, but a partial response was achieved according to the modified RECIST criteria with marked shrinkage of the tumor thrombi. Therefore, right hepatectomy with tumor thrombectomy was performed 41 days after the final administration of sorafenib. Histologically, no viable tumor cells were found in the resected specimen and pathologic complete response was confirmed. The postoperative course was uneventful, and the patient is currently alive without recurrence 2 years after the surgery.

Original languageEnglish
Pages (from-to)915-923
Number of pages9
JournalJapanese Journal of Gastroenterological Surgery
Volume46
Issue number12
DOIs
Publication statusPublished - 2013 Dec 20
Externally publishedYes

Fingerprint

Combination Drug Therapy
Cisplatin
Hepatocellular Carcinoma
Liver
Neoplasms
Thrombosis
Alcoholic Liver Diseases
Thrombectomy
Inferior Vena Cava
Hepatectomy
Portal Vein
sorafenib
Recurrence
Therapeutics
Pharmaceutical Preparations
Response Evaluation Criteria in Solid Tumors

Keywords

  • Hepatocellular carcinoma
  • Modified RECIST criteria
  • Pathological complete response

ASJC Scopus subject areas

  • Gastroenterology
  • Surgery

Cite this

A case of pathological complete response after combination chemotherapy by sorafenib and cisplatin hepatic arterial infusion for an advanced hepatocellular carcinoma. / Oguro, Seiji; Nara, Satoshi; Kondo, Shunsuke; Hori, Shutaro; Kishi, Yoji; Esaki, Minoru; Shimada, Kazuaki; Kosuge, Tomoo; Okusaka, Takuji; Ojima, Hidenori.

In: Japanese Journal of Gastroenterological Surgery, Vol. 46, No. 12, 20.12.2013, p. 915-923.

Research output: Contribution to journalArticle

Oguro, Seiji ; Nara, Satoshi ; Kondo, Shunsuke ; Hori, Shutaro ; Kishi, Yoji ; Esaki, Minoru ; Shimada, Kazuaki ; Kosuge, Tomoo ; Okusaka, Takuji ; Ojima, Hidenori. / A case of pathological complete response after combination chemotherapy by sorafenib and cisplatin hepatic arterial infusion for an advanced hepatocellular carcinoma. In: Japanese Journal of Gastroenterological Surgery. 2013 ; Vol. 46, No. 12. pp. 915-923.
@article{fb7c9067b46e4df48a7f003d3b8ff6eb,
title = "A case of pathological complete response after combination chemotherapy by sorafenib and cisplatin hepatic arterial infusion for an advanced hepatocellular carcinoma",
abstract = "Sorafenib has emerged as an effective new drug for advanced hepatocellular carcinoma. Until now, however, only a few authors have reported reduction of an advanced hepatocellular carcinoma after treatment including sorafenib, with subsequent resection. We present a case of an advanced hepatocellular carcinoma resected following combination therapy by sorafenib and cisplatin transcatheter arterial infusion. A 56-year-old man with alcoholic liver disease underwent 6 courses of combination chemotherapy by sorafenib (400 mg orally, twice daily) and cisplatin transcatheter arterial infusion (65 mg/m2, every 4-6 weeks) for a hepatocellular carcinoma in the right liver measuring 9 cm in diameter with tumor thrombi in the main portal vein and the inferior vena cava. The tumor showed stable disease according to RECIST criteria, but a partial response was achieved according to the modified RECIST criteria with marked shrinkage of the tumor thrombi. Therefore, right hepatectomy with tumor thrombectomy was performed 41 days after the final administration of sorafenib. Histologically, no viable tumor cells were found in the resected specimen and pathologic complete response was confirmed. The postoperative course was uneventful, and the patient is currently alive without recurrence 2 years after the surgery.",
keywords = "Hepatocellular carcinoma, Modified RECIST criteria, Pathological complete response",
author = "Seiji Oguro and Satoshi Nara and Shunsuke Kondo and Shutaro Hori and Yoji Kishi and Minoru Esaki and Kazuaki Shimada and Tomoo Kosuge and Takuji Okusaka and Hidenori Ojima",
year = "2013",
month = "12",
day = "20",
doi = "10.5833/jjgs.2013.0044",
language = "English",
volume = "46",
pages = "915--923",
journal = "Japanese Journal of Gastroenterological Surgery",
issn = "0386-9768",
publisher = "Japanese Society of Gastroenterological Surgery",
number = "12",

}

TY - JOUR

T1 - A case of pathological complete response after combination chemotherapy by sorafenib and cisplatin hepatic arterial infusion for an advanced hepatocellular carcinoma

AU - Oguro, Seiji

AU - Nara, Satoshi

AU - Kondo, Shunsuke

AU - Hori, Shutaro

AU - Kishi, Yoji

AU - Esaki, Minoru

AU - Shimada, Kazuaki

AU - Kosuge, Tomoo

AU - Okusaka, Takuji

AU - Ojima, Hidenori

PY - 2013/12/20

Y1 - 2013/12/20

N2 - Sorafenib has emerged as an effective new drug for advanced hepatocellular carcinoma. Until now, however, only a few authors have reported reduction of an advanced hepatocellular carcinoma after treatment including sorafenib, with subsequent resection. We present a case of an advanced hepatocellular carcinoma resected following combination therapy by sorafenib and cisplatin transcatheter arterial infusion. A 56-year-old man with alcoholic liver disease underwent 6 courses of combination chemotherapy by sorafenib (400 mg orally, twice daily) and cisplatin transcatheter arterial infusion (65 mg/m2, every 4-6 weeks) for a hepatocellular carcinoma in the right liver measuring 9 cm in diameter with tumor thrombi in the main portal vein and the inferior vena cava. The tumor showed stable disease according to RECIST criteria, but a partial response was achieved according to the modified RECIST criteria with marked shrinkage of the tumor thrombi. Therefore, right hepatectomy with tumor thrombectomy was performed 41 days after the final administration of sorafenib. Histologically, no viable tumor cells were found in the resected specimen and pathologic complete response was confirmed. The postoperative course was uneventful, and the patient is currently alive without recurrence 2 years after the surgery.

AB - Sorafenib has emerged as an effective new drug for advanced hepatocellular carcinoma. Until now, however, only a few authors have reported reduction of an advanced hepatocellular carcinoma after treatment including sorafenib, with subsequent resection. We present a case of an advanced hepatocellular carcinoma resected following combination therapy by sorafenib and cisplatin transcatheter arterial infusion. A 56-year-old man with alcoholic liver disease underwent 6 courses of combination chemotherapy by sorafenib (400 mg orally, twice daily) and cisplatin transcatheter arterial infusion (65 mg/m2, every 4-6 weeks) for a hepatocellular carcinoma in the right liver measuring 9 cm in diameter with tumor thrombi in the main portal vein and the inferior vena cava. The tumor showed stable disease according to RECIST criteria, but a partial response was achieved according to the modified RECIST criteria with marked shrinkage of the tumor thrombi. Therefore, right hepatectomy with tumor thrombectomy was performed 41 days after the final administration of sorafenib. Histologically, no viable tumor cells were found in the resected specimen and pathologic complete response was confirmed. The postoperative course was uneventful, and the patient is currently alive without recurrence 2 years after the surgery.

KW - Hepatocellular carcinoma

KW - Modified RECIST criteria

KW - Pathological complete response

UR - http://www.scopus.com/inward/record.url?scp=84891618506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891618506&partnerID=8YFLogxK

U2 - 10.5833/jjgs.2013.0044

DO - 10.5833/jjgs.2013.0044

M3 - Article

AN - SCOPUS:84891618506

VL - 46

SP - 915

EP - 923

JO - Japanese Journal of Gastroenterological Surgery

JF - Japanese Journal of Gastroenterological Surgery

SN - 0386-9768

IS - 12

ER -